Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma
Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
- Assess responses, progression free survival (PFS) and overall survival (OS) of the
combination of GIFOX-B chemotherapy with intensity-modulated radiation therapy (IMRT) in
Stage IB or bulky disease - II and without IMRT in Stage III - IV.
- Assess the toxicity and maximum tolerated dose of bortezomib administered in combination
with GIFOX chemotherapy.